RxDoctor Payments DataLook up a doctor →

Arthur Eberly, MD

Cardiovascular Disease · Greenville, SCNPI 1013973346

Payments from drug & device makers

$437,732in general payments, 2019–2025

Across 538 payments — averaging $813.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$302K
  • Amgen$69K
  • Janssen Research & Development, LLC$56K
  • Avertix Medical, Inc$2K
  • Novartis$981
  • Johnson & Johnson$586
  • plus $6K from 32 others
$8,583in research payments, 2019–2025

Across 4 payments — averaging $2145.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$9K

What the payments were for

  • Consulting fees$2,0706%
  • Speaking & faculty fees$21,00162%
  • Travel & lodging$6952%
  • Food & beverage$10,27530%
  • Education$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$437,732 in reported general payments places this provider in the 95th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$107,665
Medicare patients
767
Services billed
1,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban345$323,753
EntrestoSacubitril/Valsartan113$133,421
JardianceEmpagliflozin72$89,816
FarxigaDapagliflozin Propanediol84$85,045
Repatha SureclickEvolocumab67$69,510
XareltoRivaroxaban62$52,098
Repatha PushtronexEvolocumab66$48,437
Praluent PenAlirocumab43$27,681
Metoprolol Succinate627$8,617
Ezetimibe148$3,941
Atorvastatin Calcium377$3,347
Icosapent Ethyl14$2,970
Rosuvastatin Calcium229$2,948
Clonidine18$1,676
Losartan Potassium159$1,542

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$433$323,753345 claims
NovartisEntresto$981$133,421113 claims
Boehringer IngelheimJardiance$498$89,81672 claims
AstraZenecaFarxiga$516$85,04584 claims
Johnson & JohnsonXarelto$586$52,09862 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →